Inclusion Criteria:  Age ≥18; Evidence of histological diagnosis of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) Pathology or imaging suggested recurrence, with measurable lesions, and the number of lesions ≤3; No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney and immune deficiency Cooperative Oncology Group-Status (ECOG Status) score 0-2; Expected survival ≥3 months; Feasible abdomen and pelvic cavity MRI/CT; Good compliance, signed informed consent voluntarily.  Exclusion Criteria:  Previous radiotherapy at the target lesion site; History of active inflammatory bowel disease or severe stomach and duodenal ulcers; Human immunodeficiency virus (HIV) infected persons; active hepatitis b (HBVDNA quantitative test results exceed the lower limit), or HCV infection (HCVRNA quantitative test results exceed the lower limit); suffering from serious underlying diseases, including but not limited to active infections requiring systemic medication: patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin); neurological or mental disorders that affect cognitive ability; Patients whose lesions have been evaluated by the investigator and cannot be treated with external irradiation or endovascular radiation therapy; those who cannot follow up regularly as prescribed by the doctor; Other reasons not suitable for participating in this study as judged by the researcher.